21st Dec 2016 17:50
This announcement contains inside information
Motif Bio plc
("Motif Bio" or the "Company")
Conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces, that it has issued, in aggregate, 14,510,770 new ordinary shares in the Company ("Ordinary Shares") following the conversion by Amphion Innovations plc and Amphion Innovations US Inc., (the "Amphion Parties") of the Convertible Promissory Notes ("CPNs"). The CPNs which totalled US$3,550,786 were converted in accordance with their terms at US$0.2447 per share.
Following the conversion, the Amphion Parties will hold no further CPNs and their holding will total 43,240,645 ordinary shares being 22 per cent. of the Company.
Richard Morgan and Robert Bertoldi, Non-Executive Chairman and Executive Director of the Company respectively, are also directors of Amphion Innovations plc (the "Amphion Directors"). Amphion Innovations plc is therefore a "Person Closely Associated" with the Amphion Directors under the Market Abuse Regulation.
Application has been made for the 14,510,770 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 29 December 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 195,741,528 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
For further information, please contact:
Motif Bio plc | ||
Graham Lumsden (Chief Executive Officer) |
| |
|
| |
Zeus Capital Limited (NOMAD & BROKER) | +44 (0)20 3829 5000 | |
Phil Walker/Giles Balleny |
| |
Dominic Wilson |
| |
|
| |
Northland Capital Partners Limited (BROKER) | +44 (0)203 861 6625 | |
Patrick Claridge/ David Hignell |
| |
John Howes/ Rob Rees (Broking) |
| |
|
| |
Walbrook PR Ltd. (FINANCIAL PR & IR) | +44 (0) 20 7933 8780 or [email protected] | |
Paul McManus | Mob: +44 (0)7980 541 893 | |
Mike Wort | Mob: +44 (0)7900 608 002 | |
|
| |
MC Services AG (EUROPEAN IR) | +49 (0)89 210 2280 | |
Raimund Gabriel |
| |
| ||
This information is provided by RNS
The company news service from the London Stock Exchange
|
| |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated |
| ||||||
a) | Name
| Amphion Innovations Plc |
| |||||
2 | Reason for the notification |
| ||||||
a) | Position/status
| Person Closely Associated with PDMRs of Motif Bio Plc (Robert Bertoldi and Richard Morgan) |
| |||||
b) | Initial notification/Amendment
| Initial Notification |
| |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| ||||||
a) | Name | Motif Bio Plc |
| |||||
b) | LEI | N/A |
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| ||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares
ISIN GB00BVVT4H71 |
| |||||
b) | Nature of the transaction
| Exercise of Convertible Promissory Notes into 14,510,770 Ordinary Shares
|
| |||||
c) | Price(s) and volume(s)
|
|
| |||||
d) | Aggregated information
|
|
| |||||
e) | Date of the transaction
| 21December 2016
|
| |||||
f) | Place of the transaction
| N/A |
| |||||
Related Shares:
MTFB.L